Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
6.93
+0.42 (6.45%)
Dec 20, 2024, 4:00 PM EST - Market closed
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 133 employees as of December 31, 2023. The number of employees increased by 10 or 8.13% compared to the previous year.
Employees
133
Change (1Y)
10
Growth (1Y)
8.13%
Revenue / Employee
$112,594
Profits / Employee
-$897,662
Market Cap
425.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Dec 31, 2021 | 93 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Community Health Systems | 61,000 |
| Enhabit | 10,800 |
| National Research | 435 |
| Allogene Therapeutics | 233 |
| Alpha Teknova | 211 |
| Arcturus Therapeutics Holdings | 180 |
| Akebia Therapeutics | 167 |
| KalVista Pharmaceuticals | 150 |
GLUE News
- 8 days ago - Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - GlobeNewsWire
- 10 days ago - Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewsWire
- 10 days ago - Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - GlobeNewsWire
- 16 days ago - Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - GlobeNewsWire
- 25 days ago - Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewsWire
- 7 weeks ago - This Biotech Stock Has Doubled Its Value Today—Here's Why - Investopedia
- 7 weeks ago - Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - GlobeNewsWire
- 4 months ago - Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - GlobeNewsWire